CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Vedantra

Vedantra develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with potential application in both cancer and infectious disease.
+

Neon Therapeutics

Neon Therapeutics is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is a precision medicine company developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is entering phase III clinical trial.
+

CureTech

CureTech is a biotechnology company developing novel immune modulating products. Its lead product, pidilizumab (CT-011), was evaluated in multiple cancer indications.

See complete portfolio

Press Releases

2018

21

Oct

Biokine – BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
21

Oct

Biokine – BioLineRx Presents Top-Line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
17

Oct

גמידה סל פרסמה טיוטת תשקיף הכוללת את תנאי ההנפקה
03

Oct

BioLineRx Increases Stake in Biokine’s BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
02

Oct

Gamida Cell Made a Public Filling to the U.S. Securities and Exchange Commission in Connection with a Proposed IPO in the United States

Gamida Cell – Public filing of F-1
25

Sep

MediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid® for Sulfur Mustard Injuries

Read all Press Releases